A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kurahashi, Issei ^a   Fujita, Yoshihiko ^b   Arao, Tokuzo ^b   Kurata, Takayasu ^b   Koh, Yasuhiro ^c   Sakai, Kazuko ^b   Matsumoto, Koji ^d   Tanioka, Maki ^d   Takeda, Koji ^e   Takiguchi, Yuichi ^f   Yamamoto, Nobuyuki ^c   Tsuya, Asuka ^e   Matsubara, Nobuaki ^g   Mukai, Hirofumi ^g   Minami, Hironobu ^h   Chayahara, Naoko ^h   Yamanaka, Yasuhiro ⁱ   Miwa, Keisuke ^j   Takahashi, Shin ^k   Takahashi, Shunji ^l   Nakagawa, Kazuhiko ^b   Nishio, Kazuto ^b   more..

^a UNIVERSITY OF TOKYO   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d HYOGO CANCER CENTER   (Japan)

^e OSAKA CITY GENERAL HOSPITAL   (Japan)

^f CHIBA UNIVERSITY   (Japan)

^g NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^h KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ TOCHIGI CANCER CENTER   (Japan)

^j SAITAMA MEDICAL UNIVERSITY   (Japan)

^k TOHOKU UNIVERSITY   (Japan)

^l CANCER INSTITUTE HOSPITAL   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; APOPTOSIS; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RPL11 GENE; RPS7 GENE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UPREGULATION;

CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASMS, UNKNOWN PRIMARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84877313927     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063249     Document Type: Article

References (55)

1. Greco FA, Burris HA, Litchy S, Barton JH, Bradof JE, et al. (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 20: 1651-6.
2. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA, (2003) Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39: 1990-2005.
3. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL, et al. (2007) Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network J Clin Oncol. 25: 1747-52.
4. Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, et al. (2007) Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer 110: 770-5.
5. Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA, (2007) Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg 194: 833-7 (Disc 7-8).
6. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN, (1995) Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol 13: 2094-103.
7. Varadhachary GR, Raber MN, Matamoros A, Abbruzzese JL, (2008) Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Onc 9: 596-9.
8. Abbruzzese JL, Abbruzzese MC, Hess KR, Hess KR, Raber MN, et al. (1994) Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. J Clin Oncol 12: 1272-80.
9. Dennis JL, Hvidsten TR, Wit EC, Komorowski J, Bell AK, et al. (2005) Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res 11: 3766-72.
10. Bloom G, Yang IV, Boulware D, Kwong KY, Coppola D, et al. (2004) Multi-platform, multi-site, microarray-based human tumor classification. Am J pathol 164: 9-16.
11. Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, et al. (2001) Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol 159: 1231-8.
12. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, et al. (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci USA 98: 15149-54.
13. Shedden KA, Taylor JM, Giordano TJ, Kuick R, Misek DE, et al. (2003) Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol 163: 1985-95.
14. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, et al. (2001) Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 61: 7388-93.
15. Tothill RW, Kowalczyk A, Rischin D, Bousioutas A, Haviv I, et al. (2005) An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. Cancer Res 65: 4031-40.
16. Huber W, von Heydebreck A, Sultmann H, Poustka A, Vingron, et al, (2002) Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18: S96-S104 (Suppl 1).
17. Kurahashi I, Ito Y, Matsuyama Y, Ohashi Y, Nishio K, (2007) Evaluation of normalization methods for cDNA macroarray data (in Japanese). J Japan Statist Soc 36: 147-63.
18. Durbin B, Rocke DM, (2003) Estimation of transformation parameters for microarray data. Bioinformatics 19: 1360-7.
19. Laird NM, Ware JH, (1982) Random-Effects Models for Longitudinal Data. Biometrics 38: 963-74.
20. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc 57: 289-300.
21. Hastie T, Tibshirani R, Friedman J (2009) The Element of Statistical Learning: Data mining, Inference, and Prediction (ed 2).New York, NY: Springer.
22. Anderberg MR (1973) Cluster analysis for applications. New York, NY: Academic Press.
23. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-15.
24. Rodnina MV, Wintermeyer W, (2009) Recent mechanistic insights into eukaryotic ribosomes. Curr Opin Cell Biol 21: 435-43.
25. Ruggero D, Pandolfi PP, (2003) Does the ribosome translate cancer? Nat Rev Cancer 3: 179-92.
26. Dai MS, Lu H, (2008) Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem 105: 670-7.
27. Park JS, Yim JJ, Kang WJ, Chung JK, Yoo CG, et al. (2011) Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes 4: 56.
28. Schafer BW, Heizmann CW, (1996) The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 21: 134-40.
29. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, et al. (1997) Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J cancer 74: 464-9.
30. Melle C, Ernst G, Schimmel B, Bleul A, von Eggeling F, (2008) Colon-derived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the Ca(2+)-binding proteins S100A6 and S100A11. PloS one 3: e3767.
31. Strutz F, Okada H, Lo CW, Danoff T, Carone RL, et al. (1995) Identification and characterization of a fibroblast marker: FSP1. J Cell Biol 130: 393-405.
32. Tang DJ, Dong SS, Ma NF, Xie D, Chen L, et al. (2010) Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma. Hepatology 51: 1255-63.
33. Li XJ, Ong CK, Cao Y, Xiang YQ, Shao JY, et al. (2011) Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res 71: 3162-72.
34. Ivaska J, Pallari HM, Nevo J, Eriksson JE, (2007) Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 313: 2050-62.
35. Banh A, Zhang J, Cao H, Bouley DM, Kwok S, et al. (2011) Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. Cancer Res 71: 4423-31.
36. Um JH, Kwon JK, Kang CD, Kim MJ, Ju DS, et al. (2004) Relationship between antiapoptotic molecules and metastatic potency and the involvement of DNA-dependent protein kinase in the chemosensitization of metastatic human cancer cells by epidermal growth factor receptor blockade. J Pharmcol Exp Ther 11: 1062-70.
37. Raj L, Ide T, Gurkar AU, Foley M, Schenone M, et al. (2011) Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature 475: 231-4.
38. Jiffar T, Yilmaz T, Lee J, Hanna E, El-Naggar A, et al. (2011) KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene 30: 3163-73.
39. Fu ZY, Lv JH, Ma CY, Yang DP, Wang T, (2011) Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-κB pathway. Biomed Pharmacother 65: 163-7.
40. Macha MA, Matta A, Chauhan S, Siu KM, Ralhan R, (2010) 14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in head and neck cancer cells. BMC cancer 10: 655.
41. Soucy TA, Dick LR, Smith PG, Milhollen MA, Brownell JE, (2010) The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes & Cancer 1: 708-16.
42. Sokol JP, Neil JR, Schiemann BJ, Schiemann WP, (2005) The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta. Breast Cancer Res 7: R844-853.
43. Maier HJ, Schmidt-Strassburger U, Huber MA, Wiedemann EM, Beug H, et al. (2010) NF-kappaB promotes epithelial-mesenchymal transition, migration and invasion of pancreatic carcinoma cells. Cancer lett 295: 214-28.
44. Mao P, Hever MP, Niemaszyk LM, Haghkerdar JM, Yanco EG, et al. (2011) Serine/threonine kinase 17A is a novel p53 target gene and modulator of cisplatin toxicity and reactive oxygen species in testicular cancer cells. J Biol Chem 286: 19381-91.
45. Bandres E, Catalan V, Sola I, Honorato B, Cubedo E, et al. (2004) Dysregulation of apoptosis is a major mechanism in the lymph node involvement in colorectal carcinoma. Oncol Rep 12: 287-92.
46. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-8.
47. Singh A, Greninger P, Rhodes D, Koopman L, Violette S, et al. (2009) A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489-500.
48. Kumar MS, Pester RE, Chen CY, Lane K, Chin C, et al. (2009) Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 23: 2700-4.
49. Sun XX, Wang YG, Xirodimas DP, Dai MS, (2010) Perturbation of 60 S ribosomal biogenesis results in ribosomal protein L5- and L11-dependent p53 activation. J Biol Chem 285: 25812-21.
50. de Marval PM, Lutfeali S, Jin JY, Leshin B, Selim MA, et al. (2011) CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels. Cancer Prev Res 4: 851-9.
51. Zhu Y, Poyurovsky MV, Li Y, Biderman L, Stahl J, et al. (2009) Ribosomal protein S7 is both a regulator and a substrate of MDM2. Molecular Cell 35: 316-26.
52. Iurisci I, Cumashi A, Sherman AA, Tsvetkov YE, Tinari N, et al. (2009) Synthetic inhibitors of Galectin-1 and-3 selectively modulate homotypic cell aggregation and tumor cell apoptosis. Anticancer Res 29: 403-10.
53. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, et al. (2006) Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66: 5354-62.
54. Matta A, Siu KM, Ralhan R, (2012) 14-3-3 zeta as novel molecular target for cancer therapy. Expert Opin Ther Targets 16: 515-23.
55. Kwee TC, Kwee RM, (2009) Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol 19: 731-44.